Promising combo aims to shrink tough head and neck cancers
NCT ID NCT04862650
First seen Feb 15, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study tests whether adding an immunotherapy drug (cemiplimab) to low-dose chemotherapy can shrink tumors in people with head and neck cancer that has returned or spread. About 46 adults who have not had prior treatment for advanced disease will receive the combination. The main goal is to see if at least 40% of patients have their tumors shrink significantly after 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.